Arena Pharmaceuticals Announces the Presentation of Lorcaserin Phase 3 BLOOM Data at the American Diabetes Association's 69th Scientifi...( - Late-Breaking Abstract Accepted - ....),Health

- Late-Breaking Abstract Accepted -

SAN DIEGO, June 1, 2009 /PRNewswire-FirstCall/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) announced today that a late-breaking abstract of its lorcaserin Phase 3 BLOOM (Behavioral modification and Lorcaserin for Overweight and Obesity Management) trial has been accepted for a poster presentation at the American Diabetes Association's 69th Scientific Sessions in New Orleans, Louisiana. The abstract, titled "Lorcaserin Reduces Body Weight in Obese and Overweight Subjects: Behavioral Modification and Lorcaserin for Overweight and Obesity Management, the BLOOM Trial," will be displayed from June 6, 2009 at 10:00 a.m. Central Daylight Time (CDT) until June 8, 2009 at 4:00 p.m. CDT in the Morial Convention Center, Hall E. The poster has been assigned presentation number 96-LB in category 20-B Obesity - Clinical Treatment.

Steven R. Smith, M.D., BLOOM Co-Principal Investigator and Professor and Assistant Director for Clinical Research at the Pennington Biomedical Research Center; William R. Shanahan, M.D., Arena's Vice President and Chief Medical Officer; and Christen M. Anderson, M.D., Ph.D., Arena's Vice President, Clinical Development, will be available at the poster to discuss and address questions during two periods:

- Sunday, June 7, 2009: 6:30-7:45 p.m. CDT

- Monday, June 8, 2009: 12:00-2:00 p.m. CDT

About Lorcaserin

Lorcaserin is a novel single agent that represents the first in a new class of selective serotonin 2C receptor agonists. The serotonin 2C receptor is located in areas of the brain involved in the control of appetite and metabolism, such as the hypothalamus. Stimulation of this receptor is strongly associated with feeding behavior and satiety. Lorcaserin is currently being evaluated in a Phase 3 pro
'/>"/>